Back to top
more

Taro Pharmaceutical Industries (TARO)

(Delayed Data from NYSE)

$42.25 USD

42.25
16,938

+0.06 (0.14%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $42.24 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TARO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Taro Pharmaceutical Industries Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 850 821 1,024 1,109
Receivables NA 259 307 267 271
Notes Receivable NA 0 0 0 0
Inventories NA 227 210 180 153
Other Current Assets NA 0 0 0 0
Total Current Assets NA 1,336 1,338 1,471 1,533
Net Property & Equipment NA 190 200 206 210
Investments & Advances NA 405 435 557 460
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 104 125 142 107
Intangibles NA 17 12 0 0
Deposits & Other Assets NA 83 67 31 32
Total Assets NA 2,136 2,176 2,407 2,341
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 68 68 61 29
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 80 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 237 364 615 194
Total Current Liabilities NA 386 432 676 223
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 2 3
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 19 33 33 5
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 405 465 711 231
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 262 262 262 262
Retained Earnings NA 2,414 2,389 2,339 2,725
Other Equity NA -175 -169 -160 -157
Treasury Stock NA 771 771 746 721
Total Shareholder's Equity NA 1,731 1,711 1,695 2,110
Total Liabilities & Shareholder's Equity NA 2,136 2,176 2,407 2,341
Total Common Equity 0 1,731 1,711 1,695 2,110
Shares Outstanding 37.50 37.50 37.50 37.90 38.20
Book Value Per Share 0.00 46.16 45.64 44.74 55.23

Fiscal Year End for Taro Pharmaceutical Industries Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 902 907 806 850
Receivables NA 230 227 283 259
Notes Receivable NA 0 0 0 0
Inventories NA 215 208 205 227
Other Current Assets NA 0 0 0 0
Total Current Assets NA 1,347 1,343 1,294 1,336
Net Property & Equipment NA 218 190 190 190
Investments & Advances NA 404 388 451 405
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 97 101 101 104
Intangibles NA 17 17 17 17
Deposits & Other Assets NA 79 81 82 83
Total Assets NA 2,163 2,119 2,135 2,136
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 51 43 59 68
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 80
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 323 318 326 237
Total Current Liabilities NA 374 361 385 386
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 10 10 12 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 19
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 384 372 397 405
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 1
Capital Surplus NA 0 0 0 262
Retained Earnings NA 0 0 0 2,414
Other Equity NA 0 0 0 -175
Treasury Stock NA 0 0 0 771
Total Shareholder's Equity NA 1,779 1,748 1,739 1,731
Total Liabilities & Shareholder's Equity NA 2,163 2,119 2,135 2,136
Total Common Equity 0 1,779 1,748 1,739 1,731
Shares Outstanding 37.50 37.50 37.50 37.50 37.50
Book Value Per Share 0.00 47.44 46.60 46.36 46.16